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Abstract
Background: This paper chronicles attempts in the United States over the past 20 years to fully represent women
in clinical trials and ensure the study of sex and gender in biomedical research. We maintain that productive
science with the aim of serving the public health requires examining the influence of sex and gender on health
outcomes.
Discussion: This section provides a historical perspective on the changes in recommendations and requirements of
both the National Institutes of Health — the world’s largest single funder of biomedical research — and the U.S. Food
and Drug Administration — the world’s most influential regulator of drugs and medical devices — for the acceptable
conduct of research as it relates to sex and gender. We also cite all reports by the U.S. Institute of Medicine and the U.S.
Congress’ General Accountability Office issued from 1990 to the present on the inclusion of sex and gender in research,
and selected high-impact published studies that illustrate and document the paucity of, yet the need for, inclusion of
females and consideration of sex and gender in research across an array of biomedical disciplines.
Summary: The key message of this paper is that it has been 20 years since the first requirements to include
women as well as men in clinical trials and analyze results by sex were mandated by a U.S. federal law, yet not
nearly enough progress has been made. Recent signs of potential change in both policy and practice of scientific
inquiry suggest much more progress may be within reach. However, awaiting a cultural shift to allow the study
of sex and gender to be embraced is not seen as an effective strategy for change. Rather, specific instrumental
recommendations are offered for how to include the study of sex and gender in research so as to increase our
understanding and promotion of health for the benefit of all.
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Background
Now is the time to fully integrate the study of sex and
gender into biomedical research — a goal that is essen-
tial to productive and reproducible scientific inquiry [1],
and by so doing generate findings that advance the pub-
lic health. We focus on efforts to reach this goal in the
United States over the past 20 years since the 1994 im-
plementation of a U.S. federal law (the 1993 NIH
Revitalization Act) requiring researchers funded by the
National Institutes of Health — the world’s largest single
funder of biomedical research — to include women as
well as men in clinical studies and analyze their results
by sex or gender.
This report chronicles the changes in recommenda-
tions and requirements of both the National Institutes
of Health and the U.S. Food and Drug Administration —
the world’s most influential regulator of drugs and med-
ical devices — for the acceptable conduct of research as
it relates to sex and gender. All U.S. Institute of Medi-
cine and General Accountability Office reports on this
topic from 1990 to the present are cited, as are selected
high-impact, published studies to highlight the paucity
of, yet the continued need for, inclusion of females and
consideration of sex and gender in research across an
array of biomedical disciplines. These published studies
are woven into the historical perspective to illustrate the
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impact of the legal milestones and policy initiatives. The
scope of the report is from 1990 — the immediate prel-
ude to the 1993 NIH Revitalization Act — to the present
with an emphasis on recent developments through 2014.
We do not attempt to review the status of women’s
health research in the many other countries with scien-
tists who are committed to and actively working on the
advancement of this field.
The position advanced by this report is that steps
have been taken in the United States to remedy the un-
derrepresentation of women and the inadequate atten-
tion to sex and gender differences in research and
regulatory approvals. However, progress has been pain-
fully slow — stalling for long periods or sometimes re-
versing direction [2] — and, consequently, not nearly
enough progress has been made.
For example, women remain underrepresented in clin-
ical trials in cardiovascular disease, the primary killer of
both women and men in the United States [3], and can-
cer, the nation’s second leading cause of death for both
women and men [4]. Even when women have been in-
cluded as subjects in clinical research, the influence of
sex or gender is not widely analyzed and reported for
various health outcomes [5]. Most laboratory studies
continue to use only male animals and do not take note
of how cells differ on the basis of sex, yet these very
studies form the biological basis for human health stud-
ies and derivative treatments [6, 7].
Recognizing that the terms sex and gender are often
used interchangeably, the Institute of Medicine’s (IOM)
Committee on Understanding the Biology of Sex and
Gender Differences provided a definition of each term in
its 2011 report Exploring the Biological Contributions to
Human Health: Does Sex Matter? We follow these defi-
nitions (see Table 1: Sex and Gender Definitions [8]) in
our narrative but recognize, as did the IOM report, that
current available definitions of these terms are not un-
ambiguous and cannot always be used in a mutually ex-
clusive fashion due to the interaction of biological and
social elements affecting health outcomes [8].
The current report concludes with recommendations
regarding next steps in finally complying with the 20-year-
old requirements set by the NIH, and the inclusion of sex
and gender in biomedical research in a comprehensive
and meaningful way. It is our view that further operational
changes are needed to create a scientific environment in
which sex and gender-sensitive approaches to research are
embraced, and result in greater understanding of how
women and men are differentially affected by health con-
ditions. Importantly, we maintain that such change will re-
sult in findings for both women and men that can be
translated into improved health and healthcare.
Discussion
Milestones in the move toward inclusion
NIH and FDA: initial investigations and responses
1990: U.S. General Accounting Office Report — Problems
in Implementing Policy on Women in Study Populations.
The General Accounting Office (GAO; called the Govern-
ment Accountability Office since 2004) is the investigative
arm of the U.S. Congress and can provide reports on is-
sues of concern to the nation. This GAO report concluded
that the NIH “has made little progress in implementing its
policy to encourage the inclusion of women in research
study populations” and that the policy “has not been well
communicated or understood within NIH or in the re-
search community.” The report noted that the NIH an-
nounced the policy four years earlier, but did not publish
policy guidelines until almost three years after the an-
nouncement. Furthermore, the NIH had done little to en-
courage researchers to account for sex or gender when
analyzing study results [9].
1990: The NIH Office of Research on Women’s Health
was formed “in response to congressional, scientific and
advocacy concerns that a lack of systemic and consistent
inclusion of women in NIH-supported clinical research
could result in clinical decisions being made about
health care for women based solely on findings from
studies of men — without any evidence that they were
applicable to women.” Since its inception, the National
Institutes of Health’s Office of Research on Women’s
Health (ORWH) has promoted policies and provided
funding for research on women’s health and on the in-
fluence of sex and gender on health, and the training of
women’s health researchers within and beyond the NIH.
A key part of the ORWH’s mission continues to be en-
suring that women’s health is appropriately represented
in NIH-supported research studies [10].
1991: NIH announced the start of the Women’s Health
Initiative (WHI). This set of studies using large samples of
American women who had gone through menopause was
begun to better understand treatment for cardiovascular
disease, cancer, and osteoporosis — the major causes of
death, disability and impairment in this population of
women within the United States [11]. WHI studies collect-
ively enrolled more than 161,000 women and included an
observational study and three main clinical trials (on hor-
mone therapy, dietary modification, and calcium/vitamin
Table 1 Definitions of sex and gender
The Institute of Medicine’s Committee on Understanding the Biology of
Sex and Gender Differences provided these working definitions [8]
Sex “The classification of living things, generally as male or female
according to their reproductive organs and functions assigned
by chromosomal complement.”
Gender “A person’s self-representation as male or female, or how that
person is responded to by social institutions based on the
individual’s gender presentation. Gender is rooted in biology
and shaped by environment and experience.”
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D supplementation). These studies represented the first
nationally-representative clinical trials designed to study
key health conditions affecting women. Hormone therapy
was of particular interest as it was commonly prescribed
and increasing in use. For example, between the mid-1960s
and mid-1970s, “the number of postmenopausal estrogen
prescriptions increased markedly from an estimated nine
million to approximately 25 million” [12]. And population
surveys in the 1970s indicated that of 30 million postmen-
opausal women in the United States, one-third were re-
ceiving estrogens, often to prevent heart disease [13]. Yet,
despite this practice, only observational data were available
to support the use of hormones for the prevention of car-
diovascular disease.
1992: U.S. General Accounting Office Report — Women’s
Health: FDA Needs to Ensure More Study of Gender Differ-
ences in Prescription Drug Testing. This report highlighted
that the use of prescription drugs was the most common
form of medical treatment, and that available data
showed sex differences in the metabolism of drugs as
well as in drug interactions. Yet women were signifi-
cantly underrepresented in the clinical trials used to test
the efficacy for approximately 60 % of drugs surveyed.
When women were included, data were not analyzed for
most drugs to determine whether responses differed be-
tween women and men. The report concluded that the
FDA “should ensure that the pharmaceutical industry
consistently include sufficient numbers of women in
drug testing to identify gender-related differences in
drug response and that such sex differences are explored
and studied” [14].
1993: The NIH Revitalization Act was signed into law
on June 10, 1993. For the first time, NIH-funded investi-
gators were to be required to include women as well as
men in human subject research. For clinical trials, the
law required agency-funded investigators to “ensure
that the trial is designed and carried out in a manner
sufficient to provide for a valid analysis of whether the
variables being studied in the trial affect women or
members of minority groups, as the case may be, differ-
ently than other subjects in the trial” [15]. Cost was not
allowed as an acceptable reason for exclusion of women
and minorities. However, requiring the study of female
animals and human tissues that cannot be linked to a
living individual was not included in this legislation.
This same Act established the NIH Office for Research
on Women’s Health by law.
1993: U.S. Food and Drug Administration Guidance
for Industry: Guideline for the Study and Evaluation of
Gender Differences in the Clinical Evaluation of Drugs.
This guideline, published in July 1993, changed the FDA’s
1977 guideline excluding women of childbearing potential
from participating in early phase drug studies, which “may
have led to a more general lack of participation of women
in drug development studies, and thus to a paucity of in-
formation about the effects of drugs in women” [16]. The
new guidance allowed, but did not require, representative
inclusion of women in phase 1, 2 and 3 trials, and en-
dorsed, but did not require, analysis of data on sex differ-
ences because the FDA did not “perceive a regulatory
basis for requiring routinely that women in general … be
included in particular trials.” The agency did encourage
consideration of the effects of the menstrual cycle and of
exogenous hormone therapy on drug treatment outcomes,
and the effect of drugs on oral contraceptives’ efficacy,
when feasible (see Table 2: FDA Clinical Trials for New
Drug Approvals [17]).
1994: Requirements of the 1993 NIH Revitalization Act
took effect. In implementing the 1993 law, the NIH
Guidelines on the Inclusion of Women and Minorities as
Subjects in Clinical Research narrowed the requirement
of including women in clinical trials to phase 3 trials
only (see Table 3: NIH Clinical Trials for Human Subject
Research [18]). However, these guidelines stated that
such NIH-funded investigations must ensure that suffi-
cient numbers of women are included in a phase 3 clin-
ical trial “such that valid analyses of sex differences in
the effects of interventions can be accomplished” [19].
1998: U.S. Food and Drug Administration Final Rule:
Investigational New Drug Applications and New Drug
Applications. These new regulations published in the
U.S. Federal Register defined new drug application re-
quirements pertaining to effectiveness and safety data for
demographic subgroups, specifically gender, age and racial
subgroups. The rules did not impose any new mandates
on the conduct of studies for new drug applications, re-
quiring only safety and efficacy data that already had been
collected be presented separately for these demographic
subgroups, including men and women. The FDA did not
require any discussion or analysis of these data [20].
2000: U.S. General Accounting Office Report — Women’s
Health: NIH Has Increased Its Efforts to Include Women
Table 2 FDA clinical study phases for new drug applications
“The new drug application is the vehicle through which drug sponsors
formally propose that the FDA approve a new pharmaceutical for sale in
the United States” [17]
Phase 1 Emphasizes the assessment of safety - how a new drug
is metabolized and excreted, how a drug should be given,
how often, at what dose. It is usually conducted with a
small number of healthy volunteers.
Phase 2 Continues to test safety and begins to evaluate how well
a drug works by comparing it with a different treatment,
usually a placebo or another drug. Conducted in a larger
sample.
Phase 3 Tests the efficacy of a new drug in comparison to the
current standard, evaluates dosages and overall risk-benefit
of the drug. Conducted in a large numbers of volunteers.
Phase 4 Studies post-approval use of a drug if the FDA judges the
need to gather population data on drug safety.
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in Research. This May 2000 report concluded that sig-
nificant progress was being made in increasing represen-
tation of women in clinical trials, spurred by the fact the
inclusion of subgroup populations had become a matter
of scientific merit when research grants were assessed
for funding. However, the report found that studies still
were not routinely being designed to enable analyses by
sex, and when researchers were analyzing outcomes by
sex, these results were not always published [21].
2000: Building Interdisciplinary Research Careers in
Women’s Health (BIRCWH), a mentored career-
development program, began to train junior faculty in
interdisciplinary research on women’s health and sex
differences. This continuing program is a collaborative
effort to ensure that the influence of sex and gender on
health is studied by the next generation of scientists. It
is funded by the NIH Office for Research on Women’s
Health and its Institute partners. Since it began, the
ORWH and its BIRCWH program co-sponsors have
awarded 77 training grants to 39 institutions supporting
more than 542 junior faculty [22].
2000: FDA Amendment for Investigational New Drug
Applications addresses products intended for life-
threatening conditions that affect both genders. In June
2000, the FDA issued a new regulation allowing the
agency to halt research on drugs for life-threatening
diseases and conditions if men or women who have the
condition are excluded from study based on a per-
ceived risk to their reproductive potential. The rule
does not apply to conditions relevant to only one sex
or gender, and it does not require researchers “to enroll
or recruit a specific number of men or women with re-
productive potential” rather it seeks to remedy the his-
toric exclusion of women with a potentially deadly
condition [23].
2001: U.S. General Accounting Office Report — Drug
Safety: Most Drugs Withdrawn in Recent Years Had
Greater Health Risks for Women. This January 2001 GAO
report concluded that, of the 10 prescription drugs
approved by the FDA and subsequently withdrawn from
the U.S. market since 1997, eight of these drugs consti-
tuted a greater risk to the health of women than men
[24]. In a subsequent 2007 review, it was again demon-
strated that women suffered more adverse effects from
prescription drugs than men [25].
2001: U.S. General Accounting Office Report — Women
Sufficiently Represented in New Drug Testing, but FDA
Oversight Needs Improvement. This July 2001 GAO report
concluded that approximately one-third of applications
to the FDA for new drugs failed to meet the agency’s
1998 regulation change requiring presentation of safety
and efficacy data by sex if data were already collected. In
addition, the GAO found that the FDA had not yet exer-
cised its power to suspend research on life-threatening
conditions if men or women were excluded based on
their potential to reproduce, though the GAO report did
not examine if such a sanction should have been used in
any particular instance. And while the GAO determined
that women accounted for 52 % of study subjects for
new drug applications, women were only 22 % of those
participating in the small first phase trials used to deter-
mine dosing for later, larger efficacy trials. The report con-
cluded that the FDA had “not effectively overseen the
presentation and analysis of data related to sex differences
in drug development,” noting as an example that FDA re-
viewers failed to comment on applicants’ failures to include
dosing adjustments based on sex even though one-third of
applications “specified that the concentrations of the drug
in the bloodstream were greater in people who weighed
less, such as women.” The GAO recommended that the
FDA employ management tools to enforce its regulations
addressing sex and gender data in drug testing [2].
2001: Institute of Medicine Report — Exploring the
Biological Contributions to Human Health — Does Sex
Matter? This IOM report concluded that the study of sex
and gender differences is “evolving into a mature science.”
It provided recommendations for “establishing the condi-
tions” to encourage this science, and eliminating “barriers
to its advancement.” The report emphasized that, “Being
male or female is an important basic human variable that
affects health and illness throughout the life span,” and
recommended that “sex should be considered when de-
signing and analyzing studies in all areas and at all levels
of biomedical and health-related research” [8].
Emergence of research illustrating the importance of studying
women
2002 and 2004: Two Women’s Health Initiative trials
are halted. The most prominent of the Women’s Health
Initiative trials were two hormone therapy trials designed
to test the effects of the most commonly prescribed estro-
gen and combined estrogen/progesterone therapy at the
time of initiation of the trials. In particular, the effects of
Table 3 NIH clinical trial phases for human subject research
“Biomedical clinical trials of an experimental drug, treatment, device, or
behavioral intervention may proceed through four phases” [18]
Phase 1 Tests a new intervention in a small group of human
subjects for the first time to evaluate efficacy and safety.
Phase 2 Tests the efficacy of a new intervention in a larger group
(usually several hundred) to further evaluate efficacy and
safety.
Phase 3 Compares a new intervention to standard or to other
experimental interventions in large groups (several
hundred to thousands) to determine efficacy and to
monitor and collect data on adverse effects.
Phase 4 Assesses after-market effectiveness in the general
population and collects data on any adverse effects
associated with widespread use.
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hormone therapy on preventing cardiovascular disease,
fractures, and breast and colorectal cancer were studied
[26]. Both parts of these hormone therapy trials were
halted early, in 2002 and 2004, respectively, because inves-
tigators determined that estrogen did not appear to be pro-
tective against cardiovascular disease for which it was
generally prescribed and that health risks outweighed ben-
efits [27]. Despite subsequent controversy about the value
versus adverse effects of estrogen use, this was the first at-
tempt to investigate the benefits and risks of this widely
prescribed hormone in a large nationally-representative
longitudinal sample of women.
2005: The first randomized trial of low-dose aspirin for
cardiovascular disease prevention focusing on women
was published. In 1989, the first U.S. randomized trial of
aspirin for cardiovascular disease prevention was pub-
lished, having enrolled 22,071 men and no women [28].
Part of the Physician’s Health Study supported by the
National Heart, Lung and Blood Institute and published
in The New England Journal of Medicine, this male-only
study showed that aspirin taken every other day substan-
tially reduced risk of a first heart attack in men 50 years of
age and older, and might increase stroke risk. The findings
in this study left women and their care providers unin-
formed as to whether this preventive strategy would help,
harm or have no effect on women. The answer for women
came in 2005 in a study also published in The New
England Journal of Medicine. This Women’s Health Study
of nearly 40,000 women, 45 years of age or older who were
monitored for 10 years, showed that aspirin every other
day lowered the risk of stroke significantly for women
65 years and older without reducing coronary artery dis-
ease risk in women under 65 — clearly different effects
than in men [29]. Aspirin provided the same primary pre-
ventive benefit in women older than 65 as it did in men
50 years and over.
2005: American Academy of Orthopaedic Surgeons
(AAOS)/National Institutes of Health Workshop sum-
mary and review of studies on gender differences in
orthopedic medicine. This publication in the Journal of
Bone and Joint Surgery detailed an April 22–25, 2004
workshop sponsored by the AAOS, the leading provider
of musculoskeletal education to orthopaedic surgeons,
and the NIH. The workshop was convened to comple-
ment the Institute of Medicine’s 2001 report: Exploring
the Biological Contributions to Human Health: Does Sex
Matter? As reported from this workshop, “Musculoskeletal
problems, such as osteoarthritis, osteoporosis, spinal disor-
ders, and fractures, comprise an extremely large proportion
of visits to primary care and orthopaedic physicians; all
have a higher prevalence in women. Yet most clinicians are
unaware that the sexual differences associated with these
problems are the result of inherent differences in biology
at the cellular and molecular level.” [30].
2008: Change in life expectancy and mortality trends
in U.S. counties. In a finding specific to the United States
compared to Western Europe, Australia, New Zealand
and Japan, life expectancy was found to be falling for a
significant number of American women for the first
time since the influenza epidemic of 1918 [31]. The
study showing this, published in PLoS Medicine [32],
used federal mortality statistics and U.S. Census popu-
lation data to estimate sex-specific life expectancy for
U.S. counties for every year between 1961 and 1999.
From the early 1980s, life expectancy significantly de-
creased in 11 U.S. counties for men and in 180 counties
for women (the majority of which were in poor areas
and in the southern United States). Smoking, obesity
and high blood pressure largely led to the higher rates
of death for women.
2009: Review of sex-related influences on pain. As con-
cluded in this review in The Journal of Pain, recent find-
ings demonstrate that women have a greater risk for
many pain syndromes than do men, report greater pain
after invasive procedures, and greater sensitivity to most
forms of experimentally induced pain. The authors
recommended ways to promote progress in pain re-
search stating that “both preclinical and human studies
should routinely include subjects of both sexes.” As re-
ported, “The NIH requires this for human studies;
however, nonhuman pain research continues to eschew
females. Given that the clinical pain conditions to
which preclinical research is intended to apply are
female-predominant, one could argue that preclinical
research that excludes females is incomplete at best or
invalid at worst” [33].
2009: Studies on the relationship of the sex of patients
to the influence of general anesthesia. In reviewing
physiological and pharmacological differences between
women and men relevant to general anesthesia and re-
covery after surgery, findings published in Anaesthesia
and Intensive Care indicated that women awaken from
anesthesia faster than men, suggesting less sensitivity to
the hypnotic effects of anesthesia, but have slower recov-
ery from anesthetic drugs due to higher rates of compli-
cations or adverse effects from general anesthesia [34].
Two years after publishing this review, the authors then
confirmed their findings using a prospective, matched
cohort design with 500 patients (247 women and 253
men) who received a general anesthetic for elective sur-
gery. This study in the British Journal of Anaesthesia
showed women to be less sensitive to the drugs used,
to wake faster and to have poorer recovery than men.
These outcomes appeared to be due to sex differences in
the pharmacodynamic effects of the anesthetic drugs. Sub-
group differences were also noted in that premenopausal
women compared to postmenopausal women had worse
recovery [35].
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Further reports and studies, and a new federal law
2010: The journals Nature and Science published articles
on the paucity of female animal models in basic research.
Each of these prominent journals acknowledged the very
important lack of information in many areas of health due
to the absence of female subjects in studies using model
systems [36, 37]. Scientists discussed the problem at a
March 8–9, 2010 workshop convened in San Francisco by
the Institute of Medicine’s Forum on Neuroscience and
Nervous System Disorders [38]. “In a number of disci-
plines, researchers simply don’t study females, and there is
so much evidence for sex differences at all levels of bio-
logical organization that to only study males, and assume
the results apply to females, is just wrong” [36].
2010: Institute of Medicine Report — Women’s Health
Research: Progress, Pitfalls and Promise. This 2010 report
assessed progress in addressing health conditions that are
key to women’s health. The focus was on a number of dis-
eases or syndromes that are more common or serious for
women, or have different treatments for women than men,
or for which there was a clear unmet need for research re-
garding women. The report found major progress in breast
cancer, cardiovascular disease (CVD) and cervical cancer.
The report credited the translation of new research find-
ings in the progress made in treating these illnesses. In
addition, consumer demand for results were cited in the
case of breast cancer, and behavioral changes such as de-
creased smoking in the case of CVD. In the case of cervical
cancer, research-based improvements in diagnosis and
screening were credited as well as the development of a
vaccine to prevent human papillomavirus (HPV), the cause
of most cervical cancer [39].
The report found that research has contributed to some
improvements for women in treating depression, HIV/
AIDS and osteoporosis. Unfortunately, the report found
little research-led progress for other conditions they ex-
amined including unintended pregnancy, maternal mor-
bidity and mortality, autoimmune diseases, alcohol and
drug addiction, lung cancer, gynecological cancers other
than cervical cancer, non-malignant gynecological disor-
ders, and Alzheimer’s disease. Also of note, the report
found “inadequate enforcement of requirements that rep-
resentative numbers of women be included in clinical tri-
als,” and inadequate reporting of results on women thus
impeding “identification of potentially important sex dif-
ferences [and slowing] progress in women’s health re-
search and its translation to clinical practice” [39].
2010: NIH Office of Research on Women’s Health —
Moving into the Future with New Dimensions and Strat-
egies: A Vision for 2020 for Women’s Health Research.
This report provided a comprehensive summary of “a
two-year strategic planning process involving more than
1500 leading scientists, public policy experts, women’s
health advocates, health care providers, elected officials
and the public in five U.S. regional scientific meetings”
[10]. In generating research priorities, the plan emphasized
that it “can benefit both women and men by increasing our
understanding of the role of sex/gender factors in differen-
tial disease risk, vulnerability, progression and outcome.”
The report also predicted that “over the next decade, the
exploration of biological sex differences at multiple levels,
from genes to hormones to complex systems, will be
greatly accelerated.” Yet, “research will fall far short of its
promise to usher in an era of personalized medicine unless
the contribution of biological sex to the diversity of health
outcomes is better understood and this knowledge applied
in the development of the next generation of interventions
and medical technologies” [10].
2010: Review of women, depression and treatment de-
velopment. This review of various pharmacological, behav-
ioral and other interventional clinical trials, published in
the Journal of Women’s Health, examined the inclusion of
women as study participants and the use of gender-specific
analyses. This study found that, of 150 randomized clinical
trials published in 2007, with women averaging 56 % of the
enrolled volunteers, half the studies did not analyze results
by gender. Of 768 ongoing clinical trials, 89 % reported
recruiting both women and men, but investigators re-
ported an intention to analyze the results by gender in less
than 1 % of these studies [40]. Yet, the World Health
Organization, which ranked depression as the leading
cause of disability worldwide as of October 2012, indi-
cated that depression affects more women than men
[41].
2011: Review of sex and gender differences in cardio-
vascular disease prevention. Published in Circulation, this
review reiterated once again that more women than men
die each year in the United States from cardiovascular dis-
ease — the greatest cause of mortality for both women
and men. It pointed out that inclusion of women in clin-
ical trials for cardiovascular disease remained controver-
sial as some examinations of the data suggest an increase
in the proportion of women while others do not. None-
theless, parity in inclusion had not been achieved and ana-
lysis of outcomes by sex remained minimal with evidence
of such analyses in about one-third of studies [42].
2011: National Research Council Report — Explaining
Divergent Levels of Longevity in High-Income Countries.
This report concluded that over the past 25 years “the
United States has been falling steadily in the world
rankings for life expectancy, a surprising development
given the U.S. spends more on health care than any
other nation.” Moreover, the reduction in the rate of in-
creased life expectancy in the United States compared
to other countries examined “is starker for women than
for men.” Smoking was named a primary risk factor for
reducing life expectancy in women, followed by “obes-
ity, diet, exercise and economic inequality” [43].
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2011: Review of studies of emergency medicine for in-
clusion of gender effects on health outcomes. This review
found that the majority of published studies which fo-
cused on emergency medicine from January 2006 to
April 2009 reported gender as a demographic variable in
79 % of 750 studies. Yet, only 18 % of the studies exam-
ined health outcomes by gender. As pointed out in this
study, published in the journal Academic Emergency
Medicine, there is a tremendous need for gender-specific
analyses in this field because, “Emergency physicians as
front-line clinical specialists can directly advance patient
care by understanding how gender-specific approaches
may affect evaluation and management of diseases in the
acute setting” [44].
2011: Institute of Medicine Report — Sex Differences
and Implications for Translational Neuroscience Re-
search. Presentations and discussions from an IOM work-
shop held in San Francisco March 8–9, 2010 focused on
why it was important to study sex differences in neurosci-
ence and the need to translate findings to advance the
public health. The content for discussion focused primar-
ily on four disorders or conditions with clear gender dif-
ferences or greater health burdens for women: pain,
depression, sleep, and multiple sclerosis/neuroinflamma-
tion. The report indicated that, “sex difference research of-
fers the opportunity to determine why one sex may be
more predisposed to certain diseases, or have worse out-
comes, while the other sex is protected. Therefore, the re-
sults from sex differences research will have a significant
impact on the public health of both sexes” [38]. The key
roles of scientific journals in reporting sex differences, and
of industry in ensuring that sex differences are evaluated
in drug development were highlighted.
Among the barriers to advancing our understanding of
neurological disorders, the report included the lack of
attention to the sex of cells because “every cell has a sex
and sexual genotype (i.e., XX for females and XY for
males) which can affect the pathophysiology and preva-
lence of some diseases,” the predominant use of male
animal models in research, inadequate and inconsistent
analysis and reporting of study results by sex, and reluc-
tance of industry to conduct clinical trials that allow
analysis by sex [38].
2012: Review of studies for FDA premarket approval of
cardiovascular devices. A critique of the FDA’s actions re-
garding the development of sex-specific data for medical
devices, particularly cardiovascular devices, indicated that
women were not well represented in clinical trials for these
devices, and safety and efficacy by sex were not being ad-
equately examined [45]. For example, a review of 78 high-
risk cardiovascular devices receiving premarket approval
from the FDA between 2000 and 2007, published in Circu-
lation: Cardiovascular Quality and Outcomes [46], showed
that the FDA evidence summaries did not report sex of
participants in 28 % of 123 studies, and studies reporting
enrollment by sex had an average of 67 % men with no in-
dication of increased inclusion of women over time.
Forty-one percent of the studies had “a gender bias
comment or analysis,” which could mean that women
were not appropriately represented or that when women
were studied, a sex difference was found (see Table 4: FDA
Directive Requiring “Gender Bias” Analyses for Medical
Devices [47]). In fact, a quarter of these analyses (12 of 47)
found differences by sex either in safety or effectiveness.
Such “gender bias” comments or lack of sex-specific ana-
lyses would run counter to the 1994 FDA directive [47]
stating that “gender bias” should be reduced by studying
an appropriate ratio of male and female subjects as well as
providing safety and effectiveness data by gender. The
FDA also had convened workshops in 2008 to inform
guidance on this matter and issued draft guidance in 2011
with recommendations for increasing the number of
women and conducting sex-specific analyses.
2012: U.S. Congress enacted the 2012 Food and Drug
Administration Safety and Innovation Act, signed into
law July 9, 2012. Section 907 of the law directed the FDA
to review the inclusion and analysis of demographic sub-
groups in applications for drugs, biologics and devices by
sex, race and ethnicity, and age [48]. The review was to
take the form of a progress report of current practices and
planning for further improvement, and a subsequent Ac-
tion Plan with recommendations for enhanced enrollment
and analysis of subgroups, and communication of data to
health care professionals and the public.
2013: FDA released a progress report on the Collection,
Analysis, and Availability of Demographic Subgroup
Data for FDA-Approved Medical Products. In August
2013, the FDA reported the results of an agency-wide
working group’s investigation of 72 product applications
approved in 2011 and offered areas of improvement that
would form the basis of the following year’s Action Plan.
The progress report “concludes that the statutes, regula-
tions, and policies currently in place generally give prod-
uct sponsors a solid framework for providing data in their
applications on the inclusion and analysis of demographic
Table 4 FDA’s directive requiring “gender bias” assessment for
medical devices
The FDA’s Office of Device Evaluation directed industry, when applying
for approval of a new medical device, to address “gender bias” from
two aspects in all Premarket Approval Applications and Summaries of
Safety and Effectiveness Data by responding to the following questions
[47]
•“Was the selection ratio of men versus women in the study reflective of
the underlying distribution of the disease for that given age group,
ethnic group, stage of disease, etc.? Was any selection bias on the basis
of gender identified during review?”
•“Was there any difference in the safety and effectiveness of the device
based on gender? For example, was the device more/less effective in
women?”
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subgroups.” The report also states that, “In general, spon-
sors are describing the demographic profiles of their clin-
ical trial participants, and the majority of applications
submitted to FDA include demographic subset analyses”
[49]. This suggests that although the FDA supplies the ne-
cessary information on how sponsors should provide sub-
group data and analysis, there is not consistent reporting
by sponsors.
2013: Review of studies to determine inclusion of mi-
norities and women in clinical trials on cancer. Pub-
lished in Cancer, this study examined 304 scientific
publications reviewing both the diversity of and report-
ing on study participants in 277 treatment trials and 27
prevention trials conducted in the decade between 2001
and 2010. The large majority of subjects (greater than
80 %) were white and nearly 60 % were male. These data
also were compared to an earlier study examining inclu-
sion of women and minorities from 1990 to 2000 with
the conclusion that, “Women and racial/ethnic minor-
ities remain severely underrepresented in cancer clinical
trials, thus limiting the generalizability of cancer clinical
research” [4].
Current climate: change is possible
2014: CBS’s “60 Minutes” aired “Sex Matters: Drugs Can
Affect Sexes Differently” on February 9, 2014. With a seg-
ment by Lesley Stahl, this news show vaulted the issue of
underrepresentation of women in clinical trials and lack of
attention to sex and gender differences in research to na-
tional prominence, highlighting that, “More and more, sci-
entists are realizing that the differences between the sexes
are dangerously understudied.” The segment focused on
the example of the FDA cutting the dose recommendation
for Ambien in half for women because women metabolize
the sleep-aid drug differently than men, leaving more of it
in their system the next morning and putting them at
greater risk of accidents due to impaired functioning. The
difference was noted in a study analysis years earlier but
nothing was done about it before the drug went to market.
Although not as widely prescribed as Ambien, several
other drugs have been identified by the FDA that require
sex-sensitive prescribing [50].
2014: U.S. Surgeon General’s Report — The Health
Consequences of Smoking: 50 Years of Progress. Marking
the 50th year since the 1964 U.S. Surgeon General’s report
warned of the health hazards of smoking, this 2014 report
stated that the lifetime quit ratios for “ever smokers,”
meaning the percentage of those who had ever smoked a
cigarette and then stopped smoking, was almost the same
for women and men [51]. However, in any given quit at-
tempt, women are less successful than men, indicating
that women have more difficulty quitting [52]. Women
are also more likely than men to relapse to smoking after
quitting [53]. Moreover, female smokers may be at higher
risk for lung cancer [54], earlier age of onset for breast
cancer [55], and, compared to nonsmokers, have a 25 %
higher risk than men for coronary heart disease [56].
2014: Letter to the FDA from U.S. Senators on April
30, 2014. A bipartisan group of U.S. Senators sent a let-
ter to the FDA requesting that the agency include in its
forthcoming Action Plan a requirement for proportional
representation of women and minorities in clinical re-
search, assurance that analyses of subgroups are con-
ducted, and a process to ensure the progress of the plan
is tracked and results are made available to the public.
They voiced their shared concern “about recent evidence
that women still are not being adequately represented in
clinical trials. As a result, medical treatments may not be
as safe and effective as they may expect” [57]. One
month later, a bipartisan group of members of the U.S.
House of Representatives endorsed and delivered the
same letter to the FDA [58].
2014: Letter to the Comptroller General from members
of Congress on April 30, 2014. In a letter to the Comptrol-
ler General, 10 Democratic U.S. Senators and members of
the House of Representatives noted that 20 years had gone
by since passage of the NIH Revitalization Act requiring
appropriate representation of women and minorities and
analysis by sex for NIH-funded studies. Given that it had
been 15 years since the Government Accountability Office
updated progress on these requirements, the members of
Congress called on the GAO in this letter to the U.S.
Comptroller General to investigate and issue a report on
the participation of women in clinical trials broken down
by disease and phase of the trial. They also asked the
GAO to report the percentage of research on conditions
affecting mostly women as well as both women and men,
the ability of researchers to analyze data by sex and gender
based on available sample sizes and their commitment to
doing so, the factors affecting the enrollment of women in
clinical trials, and the current oversight of policies for
reporting on these issues by the National Institutes of
Health [59]. As of October 5, 2015, these congressional
leaders were awaiting the report.
2014: Review of studies for sex bias in surgical re-
search. This review in Surgery was the first to examine
sex bias in the 618 basic and translational science stud-
ies published from 2011 to 2012 in prominent surgery
journals. They found that when studying animals, re-
searchers did not report on the sex 22 % of the time,
and among those who did report the sex, 80 % used
only males. Among the cellular studies, 76 % did not
report the sex of the cell, and among the 24 % who did
specify sex, 71 % used only male cells. “For publications
on female-prevalent disorders, such as thyroid and car-
diovascular disease, in which one would expect a larger
number of publications studying females, only 12 %
studied females or both sexes” [60]. The authors also
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found that, over time, sex disparity in surgical research
had worsened, in that male-only studies were increas-
ingly published despite the fact that “women manifest,
progress, and react differently than men for many dis-
ease processes, including but not limited to cardiovas-
cular disease, lung cancer, depression, obesity,
osteoporosis, thyroid disorders, multiple sclerosis, and
Alzheimer’s disease” [60].
2014: National Institutes of Health on May 15, 2014
announced a change in research policy, calling for balan-
cing of sex in cell and animal studies. Increasing the
participation of women in NIH-funded clinical research
in the two decades since the 1993 NIH Revitalization
Act has helped expand knowledge about the effects of
sex and gender on health outcomes. However, accord-
ing to both the current Directors of the Office of Re-
search on Women’s Health and the NIH, “There has
not been a corresponding revolution in experimental
design and analyses in cell and animal research —
despite multiple calls to action.” They point out that
“inadequate inclusion of female cells and animals in ex-
periments and inadequate analysis of data by sex may
well contribute to the troubling rise of irreproducibility
in preclinical biomedical research” and that “the NIH is
now actively working” to confront this serious issue by
introducing improved policies in phases beginning in
October 2014 [7].
2014: The Society for Women’s Health Research sup-
ports the NIH policy change on preclinical research.
Founded in 1990 to advocate for greater public and pri-
vate funding for research on women’s health and gender
differences, the society endorsed proposed changes to
require inclusion of animals and cell types of both sexes
and stated that, “Requiring sex-based information in pre-
clinical studies as well as sex and gender-specific infor-
mation in all phases of clinical research is expected to
prevent life-threatening medical errors and unnecessary
health risks for women” [61]. The Society continues to
be highly active in education, advocacy and the promo-
tion of health research examining differences between
women and men.
2014: FDA announced its Action Plan to Enhance the
Collection and Availability of Demographic Subgroup
Data. Section 907 of the FDA Safety and Innovation Act
of 2012 required the FDA to issue an Action Plan on the
inclusion and reporting of demographic data on sub-
groups including women and minorities. In April 2014,
the FDA convened a public hearing to provide an update
on their planning and gather comments [62]. Issued in
August 2014, the Action Plan detailed 27 specific future
actions that the FDA indicated it will take in order to in-
crease the enrollment and participation of subgroups in
clinical drug trials, and improve the quality and trans-
parency of demographic subgroup data — which then
can be applied to recommendations for the use of med-
ical products [63].
2014: Federal agencies collaborating on women’s health
research. The NIH Office of Research on Women’s Health
(established 1990) and the FDA Office of Women’s Health
(established 1994) plan to collaborate on a national cam-
paign to promote the importance of clinical trial participa-
tion focusing on women [63]. These two offices have a
history of partnering to support research on women’s
health and sex differences, for example, in funding “Spe-
cialized Centers of Research on Sex and Gender Factors
Affecting Women’s Health” in various academic health
centers across the nation [7]. They also have jointly devel-
oped and offered, since 2006, an online series of courses
designed to promote research in this field and highlight
the value of considering the influence of sex and gender in
practice. These courses, such as “The Science of Sex and
Gender in Human Health,” are designed to enable “re-
searchers, clinicians and students in the health professions
to integrate knowledge of sex and gender differences and
similarities into their research and practice” [64].
Is there momentum for change?
Longstanding efforts to improve the health of women
have called for increasing the representation of women in
clinical studies, analysis of research results by sex or gen-
der, and awareness both within the research community
and the public about the essential need to study the influ-
ence of sex and gender on health. Grassroots advocacy
calling for change, new U.S. federal laws for the practice
of research, the development of federally-funded studies
on the health of women, and the establishment of inter-
disciplinary research collaborations and centers at aca-
demic health centers dedicated to women’s health have
helped advance our understanding of the many health
conditions that have sex and gender differences, or are
unique to or more prevalent in women. In sum, the
wide-ranging efforts of many people, groups and agen-
cies have made this possible.
However, it is also clear from the history presented here
that despite these hard won advancements, much more
progress is still needed. Importantly, both increased public
awareness and recent signs within key governmental agen-
cies suggest that further progress may be within reach if
we actively support the changes underway.
The National Institutes of Health, which is an influential
leader in determining the direction of research, has begun
to introduce new expectations for inclusion of female as
well as male animals and sex-typing of cell lines in basic
research [65]. Once these are approved by the White
House Office of Management and Budget, the expecta-
tions will become requirements for applications submitted
for the January 25, 2016 deadlines and beyond, and these
will be the standard when reviewing grant proposals [66].
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These would be new requirements because the changes
implemented after the 1993 NIH Revitalization Act, re-
quiring inclusion of women and minorities, excluded
representation of females in laboratory studies of
model systems and sex-typing cell lines that could not
be traced back to a particular individual. As basic sci-
ence research often lays the groundwork for much of
the clinical trials that follow, the inclusion of females
and cell typing by sex in laboratory studies could result
in a momentous change in how we conduct science
and what we will learn from scientific inquiry.
In addition, very recently, the U.S. Food and Drug Ad-
ministration issued a proposed Action Plan to reduce bar-
riers for participation and increase enrollment of women
and minorities. Just as important, the Plan proposes to in-
crease analysis of data by sex, age, race, and ethnicity, and
to post data — including in the labeling of drugs and de-
vices. Many, including members of the U.S. Congress
from both sides of the aisle, recognize this FDA plan as
a key opportunity to finally advance women’s health
and reduce risk that is related to use of medications
and medical devices.
Bolstering this new momentum, the U.S. Patient Protec-
tion and Affordable Care Act (ACA) codified the estab-
lishment of Offices on Women’s Health in major U.S.
federal agencies, including Health and Human Services,
the Centers for Disease Control and Prevention, and the
Food and Drug Administration. While many of these of-
fices existed before passage of the landmark law, the ACA
prohibits their termination, reorganization, or transfers
of powers and responsibilities without the approval of
Congress [67].
Major print and television media outlets are also paying
attention to the need for research on women’s health and
gender differences (e.g. [50, 68]). As a result, the public
has been made more aware of this issue and U.S. legisla-
tors and health officials have been prompted to call for
new policies addressing sex and gender in health research.
Clearly, there is momentum now for progress. But
how can we translate this movement into actions that
advance research and improve health and health care?
We propose that, first, it is necessary to examine and
understand the primary barriers to inclusion and, sec-
ond, to provide operational recommendations for change
that surmount these barriers by including required ac-
tions on the part of all those participating in the conduct
and translation of research.
Barriers to full participation of women as research
subjects and to the study of sex and gender differences
Until relatively recently, the prevailing scientific tradition
was to not include women in clinical trials. Of note, even
the first trial testing the effect of estrogen on secondary
prevention of coronary heart disease, published in The
Journal of the American Medical Association in 1973, was
conducted solely with men, enrolling 8341 men and no
women [69].
Three major reasons appear to account for the exclusion
of women as research subjects, and even when women
were included, not analyzing data by sex or gender.
First, women were ruled out of participation based on
concerns about exposure to experimental risk during
childbearing years. However, these concerns led to in-
dustry and government research policies that effectively
excluded all women. Women’s health became conflated
with women’s reproductive health and child health, and
this narrow view persists in some quarters to this day.
Furthermore, excluding women of childbearing age “as-
sumes that women lack any control over their child-
bearing potential while participating in clinical trials”
[70]. In fact, excluding all women of any age assumes
that women, whether premenopausal or postmeno-
pausal, cannot make informed judgments.
Protectionist perspectives have also represented women
as being vulnerable to unwilling participation, and these
perspectives still persist. For example, the Code of Federal
Regulations of the NIH Office for Protection from Re-
search Risks maintains criteria for Internal Review
Board approval of research which includes the follow-
ing provision: “When some or all of the subjects are
likely to be vulnerable to coercion or undue influence,
such as children, prisoners, pregnant women, mentally
disabled persons, or economically or educationally dis-
advantaged persons, additional safeguards have been in-
cluded in the study to protect the rights and welfare of
these subjects” [71].
Over time, many overly protectionist policies that ex-
cluded women are coming to be viewed as discrimin-
atory and lacking in scientific merit [16, 72]. However,
some of these policies continue [71] and often remain in
less obvious ways as well, for example through uncon-
scious biases within the general culture [1, 73, 74], which
results in women continuing to be underrepresented as
participants in many areas of clinical research and in
data on health outcomes infrequently analyzed by sex or
gender. Clearly, the existence of unconscious bias must
be recognized and tempered if we are to remedy its ef-
fects on sound scientific inquiry.
Second, misperceptions persist among some medical
professionals and among segments of the public that
women are less affected by certain disorders or health
conditions and, when affected, that women respond to the
same treatment as men. For example, cardiovascular dis-
ease (CVD), an area in which women have not been ad-
equately studied, is the leading killer of women as well as
men in the United States and most developed countries.
Yet, as recently as 2005, an American Heart Association
random survey of 500 physicians found that women were
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more likely than men to be deemed at lower risk of car-
diovascular disease and less likely to be referred for diag-
nostic tests, despite similar risk. This study also found that
“Fewer than 1 in 5 physicians knew that more women
than men die each year from CVD” [75]. More recently, a
2007 study using a national sample of commercial health
plans found that, despite similar access to care, women
were less likely than men to receive recommended care
for cardiovascular disease [76].
Cardiovascular disease also provides a clear illustra-
tion of treatment responses that can differ by gender.
Studying only men, researchers learned in 1989 that
low dose aspirin reduced the risk of a first heart attack
in men 50 years and older by 44 % yet possibly in-
creased stroke risk [28]. It took another 16 years for a
study to show that low-dose aspirin was not effective in
primary prevention of coronary artery disease risk in
women under 65 but it was for women older than 65,
and that aspirin reduced the risk of stroke in women
65 years and older [29].
The possibility of a sex-specific treatment response still
is not being routinely taken into account. As shown in a
2010 survey of cardiovascular disease prevention clinical
trials, published in Circulation: Cardiovascular Quality
and Outcomes, “differences in treatment effect by sex were
not commonly presented in the literature and that this
practice has not changed over time” [3]. And, as demon-
strated in the current report, cardiovascular disease is
just one of many areas of health in which greater
awareness and understanding of gender effects will im-
prove health care.
Third, women are perceived as bringing complexity
and thus increased cost and the need for greater ana-
lytical capability to scientific design. Including women
in research studies, as the Institute of Medicine notes
in its 2001 report, “introduces additional variables (in
the form of hormonal cycles) and decreases the homo-
geneity of the study population” [8]. Yet, as the Insti-
tute of Medicine report also concludes, “being male or
female is an important basic human variable that
should be considered when designing and analyzing
studies in all areas and at all levels of biomedical and
health-related research.” Until sex and gender differ-
ences are routinely investigated and the results are
routinely reported “many opportunities to obtain a bet-
ter understanding of the pathogenesis of disease and to
advance human health will surely be missed” [8].
Interestingly, in a survey of 10 different biological fields
of study using non-human mammals and then in a meta-
analysis of neuroscience and biomedical research studies
using mouse models, biological variability was not found
to be significantly greater in females than males. As
pointed out in these studies, this finding, coupled with the
occurrence of sex differences at “all levels of biological
organization” warrant inclusion of female animals to en-
sure good science [77, 78]. Moreover, a recent 2014 Com-
ment in Nature co-authored by the Director and Deputy
Director of the National Institutes of Health points to ig-
noring sex differences as among the factors contributing
to the growing concern of reduced scientific reproducibil-
ity in pre-clinical research [1].
In order to overcome these barriers, it is essential to
implement consensus requirements for change. As the
chronology in this report indicates, recommendations
for actions to ensure the inclusion of sex and gender in
research studies have been made by national academies,
scientific committees, and leading scientists that have
yet to be carried out. Whether existing or new, the fol-
lowing recommendations are valuable guides for imple-
menting practices that improve our research capabilities
and should be adopted now.
Recommendations for change
1. The leading national agencies in biomedical research
and in the approval of drug/device interventions,
specifically the NIH and the FDA within the United
States, must take the lead in both enforcing existing
requirements and extending research design and
analysis requirements to ensure adequate inclusion
of women and investigations that provide meaningful
analysis by sex and gender [1, 7, 63]. These strategies
for inclusion should serve as a model for all
government agencies that fund or conduct
research [39].
With regard to the National Institutes of Health:
2. The opportunity to study women’s health and the
influence of sex and gender on health should be
central to the goals of the NIH and a key feature of
the newly developing NIH-wide Strategic Plan [79].
2.1.Development of both funding mechanisms and
methodologies for collecting larger sample sizes
that facilitate the analysis of sex and gender
differences should be included in this plan [39].
2.2. As part of the Strategic Plan, each Institute
should be required to provide data annually on
its independent funding of research on women’s
health, its plan for establishing how the influence
of sex and gender are routinely examined in
mainstream research, and its contribution to
collaborative funding with the NIH Office of
Research on Women’s Health.
2.3.When making funding decisions, priority
should be given to proposals that show
methods and designs providing for inclusion
and analysis by sex and gender. As the journal
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Nature points out in a 2010 editorial,
“Funding agencies should demand that
researchers justify sex inequities in grant
proposals and, other factors being equal,
should favor studies that are more
equitable” [80].
2.4.In laboratory research using cell lines, the
effects of the sex of cells must be investigated
and reported [6–8].
With regard to the NIH and the FDA:
3. Research applications to the NIH that study women
across varying risk subgroups, ages, race/ethnicities,
social and behavioral factors should also be favored
for research funding because not all women are the
same [39]. Information and analyses on subgroups
should also be part of FDA new drug applications.
As the FDA’s recently issued Action Plan notes,
“Making sure that different demographic subgroups
are sufficiently represented in clinical trials and
enhancing the analyses and public availability of
subgroup data will contribute to development of a
sound knowledge base as we move toward a time
when all stages of patient care — from prevention to
diagnosis to treatment to follow up — are truly
personalized” [63].
4. The effects of hormonal factors on research outcomes
should be investigated and understood as a further
important refinement of subgroup differences with
regard to reproductive status, the menstrual cycle,
oral contraceptive use, menopause, and hormone
therapies [8, 16].
5. In studying drug effects, both the sex differences in
the way a drug is metabolized (pharmacokinetics)
and the clinical response to drug concentrations
(pharmacodynamics) should be investigated and
reported. The empirical data that served as the
rationale for this recommendation over 20 years ago
in the 1993 FDA Guideline for the Study and
Evaluation of Gender Differences in the Clinical
Evaluation of Drugs [16] continues to be replicated
[24, 25, 81] and the FDA should be responsive to
these findings in its requirements.
6. In studying medical devices, there must also be
sex-specific data on safety and efficacy on all
products [45, 47].
7. Reproductive considerations for participation in
clinical intervention trials, such as for drug
therapies, should be extended to men. If there is
concern that exposure to an experimental condition
could induce harm in reproductive capacity in
women, parallel concern about inducing harm in
men should be considered [70].
With regard to scientific publications and peer reviews:
8. Publishers and editors of all scientific and medical
journals must expand existing policies and go beyond
simply recommending inclusion of descriptive data on
sex of subjects [82].
8.1.Policies should ensure the inclusion and analysis
of sex-specific data in clinical studies, as well as
sufficient sample sizes to allow analysis of results by
gender and sex. As the Institute of Medicine
recommended in its 2010 report, “The International
Committee of Medical Journal Editors and other
editors of relevant journals should adopt a guideline
that all papers providing the outcomes of clinical
trials report on men and women separately unless a
trial is of a sex-specific condition (such as
endometrial or prostatic cancer)” [39]. The
Journal of the National Cancer Institute was the
first journal to include instructions to authors
for addressing the effects of sex as part of its
manuscript-preparation policy. And in fact, the
practice and experience of this journal demonstrate
that sex-specific analysis and reporting is possible,
and “there has been no pushback since the
institution of the policy” [5].
8.2. The inclusion of female animals and cells in
laboratory studies on health conditions suffered
by women as well as analysis by sex should also
be a prerequisite for manuscript consideration.
8.3. It should be the responsibility of peer reviewers
of both manuscripts and grant proposals to
inquire as to these types of analyses if they are
not provided. And as proposed by the Directors
of the NIH and the ORWH, reviewers within
the NIH review process should be “enjoined to
evaluate applicants’ research plans to include,
compare and contrast experimental findings in
male and female animals and cells” [7].
8.4. The Institute of Medicine’s 2012 workshop
summary report provides a blueprint on
sex-specific reporting strategies that can be
adopted.
8.4.1.For example, in reporting on clinical studies,
the IOM report recommends: a) “The title
and abstract should indicate whether a
study involved only men or only women.” b)
“If the study design allows identification of
sex differences, journals should require
authors to present these results.” c) “If there
is an inability to identify sex differences, this
should be reported in the discussions of the
limitations of the study” [5].
8.4.2.In reporting on preclinical studies, the IOM
report recommends: a) “The sex of the
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animals studied should be reported.” b) “If
only one sex of an animal was studied, this
should be indicated in the title of the
article.” c) “In most cases, the sex of origin
of cells used should be reported (excluding,
for example, immortalized cell lines, which
are highly transformed and for which the
sex of the original cells may not be relevant).”
d) “Both male and female animals should be
studied when appropriate; and, when it is
possible, both sexes should be studied in the
same experiment” [5].
With regard to training of scientists and clinicians:
9. The influence of sex and gender on health and
treatment outcomes should be integrated into the
training of researchers and clinicians [64].
9.1.The scientific training of all clinical and
laboratory biomedical researchers should focus
on the value of including sex and gender as
primary variables of study in order to enhance
the precision and reproducibility of scientific
inquiry. Learning how sex and gender affect
outcomes can provide a basis for the motivation
to embrace research that focuses on women’s
health and sex differences.
9.2.Findings derived from research on the influence of
sex and gender on health must be incorporated
into the education of health care professionals.
Strategies for incorporating data on sex and
gender health effects into health curricula are
rapidly developing and professional resources are
available to facilitate this process [83, 84].
9.3.Similarly, medical educators must provide
instruction in sex and gender effects on health in
continuing medical education in order to
ultimately optimize health care for all.
With regard to the translation and communication of
research findings:
10.Sex-specific research findings should be provided to
the community. After due diligence in ensuring the
reliability and validity of scientific results, there must
be a concerted effort by those overseeing the
funding, direction and conduct of research along
with clinical practice partners to ensure appropriate
translation of findings and expedite this information
for the benefit of all.
10.1.The challenges in translating research results
must be met by government agencies requiring
researchers to discuss the translation of findings,
and by professional medical associations requiring
that clinical practice guidelines routinely
incorporate sex-specific findings [39].
10.2.Communication methods for new health
information must be developed by academic
health centers, federal agencies such as the NIH
and FDA, and professional medical societies.
Data of practical benefit must be disseminated
in understandable language accounting for
subgroup differences and possible conflicting
data. Distribution of information through
central clearinghouses, such as research
institutes and professional society websites,
should be coordinated and regulated to allow
the public access to how research works and
how to know what to take from its findings.
With regard to research, the Institute of Medicine’s
2012 report notes that “a culture shift within science”
must occur to make the changes necessary to fully incorp-
orate the study of sex and gender in health research [5].
We maintain that to effect a culture change it is necessary
to turn the recommendations suggested here into require-
ments for research, coupled with rewards for following
mandated guidelines. The approach to making positive
change must be to reward and reinforce those who take a
stand for gender-specific medicine, knowing that the
change we make will result in advancements in well-being
for both women and men.
Other actions also must be taken to advance the health
of women and men. As healthcare consumers, we must
ask our health care professionals about available research
on how sex and gender may influence treatment deci-
sions. Consumers and health care professionals alike
need to express their support for research that has ad-
equate representation of females and for analyses and
reporting of study results by sex and gender. Federal and
some state tax dollars provide much of the support for
biomedical research in the United States, and legislators
set the priorities and oversee the budgets for such
government-supported research. Consequently, our law-
makers must be reminded of the importance of studying
the effects of sex and gender across health conditions
when making research funding decisions [85].
Conclusion
Various efforts over the last 20 years have been made to
ensure that the influence of sex and gender on health is
part of our national research agenda and that research
findings are translated into practice. As a function of
continuing public scrutiny and congressional review over
two decades, progress has been made. For example, the
National Institutes of Health, which influences the direc-
tion of research, now requires that women be considered
as subjects in NIH federally-funded clinical trials as
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prescribed by law and is expected to require the inclu-
sion of females in studies using animal model systems
and of sex-typing in studies of cells. The U.S. Food and
Drug Administration, which regulates all prescription
drugs and devices, has now issued an Action Plan which
presumably will incorporate to some degree the study of
sex differences in the approval process for drugs and de-
vices. Due to the emergence of research illustrating the
value of studying women and sex differences, public and
professional awareness has grown as to how this is im-
portant to good science and to the public health.
However, progress has been slow and halting, and we
have not achieved sufficient progress in order to truly
serve the public health. To remedy this, specific recom-
mendations for change are provided. For example, the
NIH should offer priority to grant applications addressing
sex and gender differences, and the FDA should require
sex-specific data for all drug and device applications. The
Institute of Medicine’s 2012 report notes that “a culture
shift within science” must occur to make the changes ne-
cessary to fully incorporate the study of sex and gender in
health research [5]. We maintain that to effect a culture
change it is necessary to overcome the barriers to positive
change by turning the recommendations suggested here
into requirements for research, coupled with rewards for
following mandated guidelines.
In addition, we must all participate in creating change,
and accountability has to be built into the process of
implementing change. This includes requiring that med-
ical and continuing medical education incorporates con-
sideration of the influence of sex and gender on health.
The editors of medical journals should not consider stud-
ies that fail to include analysis of sex and gender unless
studies are investigating conditions that affect one sex or
gender. Consumers and legislators must also show their
support for research that has appropriate representation
of females and analyzes and reports results by sex and
gender. With these types of changes and a commitment
from all sectors, productive change is feasible and will her-
ald better health for all.
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